Vertex Signs a 4 Years Agreement with Kymera to Discover and Develop Protein Degradation Therapies


  • Kymera to receive $70M upfront including equity investment, >$1B as development, regulatory & commercial milestones for up to 6 therapies opted by Vertex, royalties on sales of products and is responsible for clinical research activities. Vertex to get an option to license the developed molecules against designated targets
  • The focus of the collaboration is to broaden the application of Kymera’s Pegasus drug discovery platform by developing therapies for serious diseases with limited/no treatment options
  • Kymera’s Pegasus is a protein degradation platform consists of driven target identification, E3 ligases, ternary complex predictive modeling capabilities, and degradation tools accelerating the drug discovery process by targeting intractable of proteins

Click here to read full press release/ article | Ref: Vertex | Image: Biomedrealty